recognition of the existence of this or of other similar inhibitors in bleeding patients is important because of the potential for treatment with agents such as protamine sulfate and platelet factor 4 , which neutralize the anticoagulant effects of proteoglycans .
C0019080
bleeding
C0033602
protamine sulfate